Company news
Verastem, Inc. (NASDAQ:VSTM) news
Every Verastem, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, ...
September 8, 2026
Verastem Oncology to Participate in Upcoming September Investor Conferences
September 2, 2026
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
August 6, 2026
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor fo...
July 28, 2026
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-S...
July 22, 2026
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patie...
June 23, 2026
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-o...
June 17, 2026
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor fo...
June 16, 2026
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor ...
June 15, 2026
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (O...
June 3, 2026
Verastem Oncology to Present at Jefferies Healthcare Conference
May 27, 2026
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
May 26, 2026
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 7, 2026
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurr...
April 30, 2026
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy in Recurrent Low-Grade Serous Ovarian ...
April 13, 2026
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib t...
April 10, 2026
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules
March 18, 2026
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combina...
March 17, 2026
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
March 17, 2026
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
March 4, 2026
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
February 18, 2026
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for No...
February 4, 2026
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
December 29, 2025
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
December 15, 2025
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
November 25, 2025
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
November 14, 2025
Verastem Oncology Announces Proposed Public Offering of Common Stock
November 13, 2025
Verastem Oncology to Present at Upcoming Investor Conferences
November 5, 2025
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
November 4, 2025
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
October 23, 2025
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/...
October 23, 2025
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in ...
October 19, 2025
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non...
August 13, 2025
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
August 7, 2025
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
July 29, 2025
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancre...
July 24, 2025
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defact...
July 11, 2025
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Com...
June 30, 2025
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G1...
June 24, 2025
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12...
June 2, 2025
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
May 28, 2025
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-o...
May 22, 2025
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
May 13, 2025
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Gr...
May 8, 2025
Verastem Oncology Announces $75 million Private Placement
April 25, 2025
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid...
April 23, 2025
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
March 25, 2025